详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Hydration for prevention of kidney injury after primary coronary intervention for acute myocardial infarction: a randomised clinical trial.

8| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, The Affiliated Guangdong Provincial People’s Hospital of South China University of Technology, Guangzhou, Guangdong, China [2]Cardiology, Peking University First Hospital, Beijing, China [3]Cardiology, The First Medical Center, Chinese PLA General Hospital, Beijing, China [4]Cardiology, The Affiliated Hospital, Guangdong Medical University, Zhanjiang, Guangdong, China [5]Cardiology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China [6]Cardiology, Longyan First Affiliated Hospital, Fujian Medical University, Longyan, Fujian, China [7]Cardiology, Dongguan People’s Hospital, Dongguan, Guangdong, China [8]Cardiology, Maoming People’s Hospital, Maoming, Guangdong, China [9]Cardiology, The First People’s Hospital of Zhaoqing, Zhaoqing, Guangdong, China [10]Cardiology, Shenzhen People’s Hospital, Shenzhen, Guangdong, China [11]Cardiology, Beijing Ditan Hospital, Capital Medical University, Beijing, China [12]Cardiology, Hangzhou First People’s Hospital, Hangzhou, Zhejiang, China [13]Cardiology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China [14]Cardiology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [15]Cardiology, Mianyang Central Hospital, Changjia Alley 12, Fucheng District, Mianyang, Sichuan, China [16]Biostatistics, The State Key Laboratory of Organ Failure Research, The Key Laboratory of Tropical Disease Research, School of Public HealthMedical University, Guangzhou, Guangdong, China [17]Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China [18]Neurology, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA

出处：

DOI：

ISSN：

摘要：

To evaluate the efficacy of aggressive hydration compared with general hydration for contrast-induced acute kidney injury (CI-AKI) prevention among patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI).The Aggressive hydraTion in patients with STEMI undergoing pPCI to prevenT Contrast-Induced Acute Kidney Injury study is an open-label, randomised controlled study at 15 teaching hospitals in China. A total of 560 adult patients were randomly assigned (1:1) to receive aggressive hydration or general hydration treatment. Aggressive hydration group received preprocedural loading dose of 125/250 mL normal saline within 30 min, followed by postprocedural hydration performed for 4 hours under left ventricular end-diastolic pressure guidance and additional hydration until 24 hours after pPCI. General hydration group received ≤500 mL 0.9% saline at 1 mL/kg/hour for 6 hours after randomisation. The primary end point is CI-AKI, defined as a >25% or 0.5 mg/dL increased in serum creatinine from baseline during the first 48-72 hours after primary angioplasty. The safety end point is acute heart failure.From July 2014 to May 2018, 469 patients were enrolled in the final analysis. CI-AKI occurred less frequently in aggressive hydration group than in general hydration group (21.8% vs 31.1%; risk ratio (RR) 0.70, 95% CI 0.52 to 0.96). Acute heart failure did not significantly differ between the aggressive hydration group and the general hydration group (8.1% vs 6.4%, RR 1.13, 95% CI 0.66 to 2.44). Several subgroup analysis showed the better effect of aggressive hydration in CI-AKI prevention in male, renal insufficient and non-anterior myocardial infarction participants.Comparing with general hydration, the peri-operative aggressive hydration seems to be safe and effective in preventing CI-AKI among patients with STEMI undergoing pPCI.© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

基金：

基金编号： LHJJ20141751 2014dzx02 81670339 81500520 2020B1111170011 2017B030314041

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 2 区心脏和心血管系统

最新[2025]版：

大类 | 2 区

医学

小类 | 2 区心脏和心血管系统

JCR分区：

出版当年[2020]版：

Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

最新[2023]版：

Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子： 5.1 最新[2023版] 5.6 最新五年平均 5.994 出版当年[2020版] 6.308 出版当年五年平均 5.213 出版前一年[2019版] 7.369 出版后一年[2021版]

第一作者：

第一作者机构： [1]Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, The Affiliated Guangdong Provincial People’s Hospital of South China University of Technology, Guangzhou, Guangdong, China

共同第一作者：

通讯作者：

通讯机构： [1]Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, The Affiliated Guangdong Provincial People’s Hospital of South China University of Technology, Guangzhou, Guangdong, China [*1]Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, The Affiliated Guangdong Provincial People’s Hospital of South China University of Technology, Guangzhou, Guangdong, China

推荐引用方式(GB/T 7714)：

APA：

MLA：